In this episode, Dennis Walker speaks with Dr. Jonathan Fields, an integrative medicine specialist who is currently petitioning the DEA to respect the ‘Right to Try Laws’ in relation to empowering terminally ill patients to legally access psilocybin therapy.
Similar Posts
MindMed Management Update & Earnings Call [ MMED / MNMD / MMQ]
Here’s MindMed’s (MMED / MNMD / MMQ) Q1 2021 recorded Earnings call! Soon we will upload a video detailing all the highlights but for now, for those who are interested in listening to the entire call, you can listen to it here!
Enjoy!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNews #MNMD
Interview With Steven Huang, DEI Consultant at MAPS and Numinus
Steven’s consultancy company, Millennial HR Design, focuses on the intersection of DEI and psychedelics, where he intends to be a leverage point for the psychedelics industry to better understand their impact on marginalized communities. With nearly 10 years of industry experience, Steven hopes for more diverse and equitable representation in the psychedelic space.
MindMed Releases Data on TWO Clinical Trials: A Closer Look Into MMED’s Psilocybin and LSD studies
MindMed Releases Data on TWO Clinical Trials: A Closer Look Into MMED’s Psilocybin and LSD studies.
Mind Medicine (MindMed), (NASDAQ: MNMD, NEO: MMED, DE: MMQ), announced that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany, conducted as part of MindMed’s ongoing collaboration with the UHB Liechti Lab.
STUDIES:
https://clinicaltrials.gov/ct2/show/NCT03912974?term=psilocybin+escitalopram&draw=2&rank=2
https://clinicaltrials.gov/ct2/show/NCT03604744?term=LSD+PSilocybin&draw=2&rank=1
https://mindmed.co/news/press-release/mindmed-and-liechti-lab-provide-results-from-their-psilocybin-rd-collaboration/?fbclid=IwAR2_2fUvNf-VTF36Sv6Oz-XB8PTjscqjMWMFF5CKBvKQU2yLMOI_ZP4aq18
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#mindmed #mmed #mnmdstock
The DEA Backs Down, Will Not Criminalize 5 Psychedelics
This week the DEA announced it would withdraw its plan to schedule 5 research psychedelics. But we shouldn’t celebrate just yet
California Senate Votes in Favor of Legalizing Natural Psychedelics
SB-58 would legalize the personal use of certain amounts of psilocybin, psilocyn, DMT, ibogaine, and mescaline.